Foghorn Therapeutics Inc (FHTX) Unusual Options Activity Today

Checking FHTX unusual options activity helps you spot when traders are making outsized bets on Foghorn Therapeutics Inc before the broader market catches on. Foghorn Therapeutics Inc's unusual options activity flags contracts trading at multiples of their average daily volume, often signaling that informed money is positioning ahead of a catalyst. Use our scanner to monitor FHTX unusual options activity today and surface the prints that deserve a second look.

Unusual options flow typically refers to trades where volume vastly exceeds open interest at a given strike, or where total contract volume on a name spikes well above its norm. Watching FHTX unusual options flow today can reveal large block trades, sweeps across exchanges, and aggressive directional bets. Tracking FHTX unusual options volume across calls and puts helps you separate hedging activity from genuinely speculative positioning, and FHTX unusual options flow data becomes especially valuable around earnings, product launches, and macro events.

Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines targeting genetically determined dependencies within the chromatin regulatory system. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It is developing FHD-286, a small molecule inhibitor of the enzymatic activity of BRG1 and BRM for the treatment of metastatic uveal melanoma and relapsed and/or refractory acute myeloid leukemia and myelodysplastic syndrome; and FHD-609, a small molecule protein degrader for BRD9 to treat patients with synovial sarcoma.

The company is also developing an enzymatic inhibitor and a protein degrader as selective modulators of BRM; and ARID1B selective modulators for the treatment of ovarian, endometrial, colorectal, bladder, and gastric cancers. It has a research collaboration and license agreement with Merck Sharp & Dohme Corp. to discover and develop novel oncology therapeutics against a transcription factor target; and with Loxo Oncology to create novel oncology medicines. Foghorn Therapeutics Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Catalysts rarely arrive without a footprint, and FHTX unusual options activity is often where that footprint shows up first. Our scanner tracks Foghorn Therapeutics Inc's unusual options flow in real time, ranks prints by volume-to-open-interest, premium spent, and aggressor side, and separates real conviction from noise. Whether you're looking at FHTX unusual options volume on the call side or chasing put sweeps, Foghorn Therapeutics Inc's unusual options flow today is one click away, so put it on your radar before the headlines hit.